Cordis continues to pioneer minimally invasive treatments for cardiovascular disease and is committed to delivering products and services supported by clinical evidence to help optimise patient outcomes.
The Cordis Outback Re-Entry Catheter is designed to get back into the true lumen at the reconstitution point to ensure optimal patient outcomes. This helps to reduce radiation exposure time on average re-entry takes only eight minutes .
read full descriptionThe S.M.A.R.T. CONTROL Iliac Stent System is designed to improve luminal diameter in patients with symptomatic atherosclerotic disease of the iliac arteries up to 126 mm in length, with a reference vessel diameter of 4 to 9mm, and angiographic evidence of a patent profunda or...
read full descriptionThe Saber A ngioplasty (PTA) dilatation catheter is designed for the treatment of patients with peripheral arterial disease. It is cleared for use and available in Europe, the United States and Japan. The 0.018-inch PTA balloon catheter is intended to dilate stenoses in iliac, femoral,...
read full descriptionThe TRAPEASE Permanent Vena Cava Filter from Cordis is designed for the treatment and prevention of recurrent pulmonary embolism. The filter is deployed via a 6F sheathed induction kit. The updated temporary version is the OptEase filter. 'A brief history of inferior...
read full descriptionWhichMedicalDevice is a FREE resource created by clinicians for clinicians.
Registration is free and gives you unlimited access to all of the content and features of this website.
Find out more...Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...
Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.
We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.